Please assess the completion status of the following clinical trial:

Trial Title: A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Main Inclusion at Screening (Visit 1):~* Men and women 19 years or older with OAB symptoms for ≥ 3 months.~* Subject who is willing and able to complete the micturition diary correctly.~* Subject who is willing and able to provide informed consent indicating that they understand the purpose and procedures required for the study~Exclusion Criteria:~* Clinically significant Stress urinary incontinence or Mixed urinary incontinence where stress is the predominant factor~* Diagnosed with interstitial cystitis or bladder pain syndrome~* Clinically significant pelvic organ prolapse~* Subject who has neurologic status which is able to effect vesical function, such as multiple sclerosis, Spinal Injury or Parkinson's disease~* Medical history of malignant tumor in urinary system or pelvic organs~* Clinically significant bladder outlet obstruction or more than 200mL of post-void residual volume

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): DA-8010 placebo + Solifenacin succinate placebo
- DA-8010 2.5mg (Type: EXPERIMENTAL): DA-8010 2.5mg + Solifenacin succinate placebo
- DA-8010 5mg (Type: EXPERIMENTAL): DA-8010 5mg + Solifenacin succinate placebo
- Solifenacin 5mg (Type: ACTIVE_COMPARATOR): DA-8010 placebo + Solifenacin succinate 5mg

Based on this trial design, predict the completion outcome and termination type (if applicable).